Business Context and Reporting Period
This Form 8-K Current Report is filed by Phibro Animal Health Corporation (PAHC) on June 26, 2026, regarding events occurring on June 25, 2026. The filing discloses the appointment of a new Chief Executive Officer and President and the associated compensation arrangements.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation terms.
- Base Salary: $850,000 annually.
- Target Bonus: 50% of base salary ($425,000).
- Annual Equity Target: Approximately 50% of base salary in time-vesting RSUs.
- Initial Equity Grant: 300,000 Restricted Stock Units (RSUs).
Material Changes
The primary material change is the leadership transition effective July 1, 2026:
- Appointment: Daniel (Dani) Bendheim is appointed as Chief Executive Officer and President.
- Compensation Structure: A new employment agreement and performance-based equity award were approved by the Compensation Committee.
Guidance, Outlook, and Risks
Equity Vesting Conditions: The 300,000 Initial RSUs are subject to performance-based vesting on June 30, 2031, contingent on the Company's stock price:
- Threshold: No vesting if the 90-day average closing stock price is below $70.
- Target: 100% vesting if the 90-day average closing stock price is $100 or above.
- Interpolation: Linear interpolation applies for prices between $70 and $100.
Termination Provisions:
- Death/Disability: Eligible for six months of continued base salary.
- Without Cause/Good Reason: Eligible for up to 18 months of Company-subsidized COBRA coverage.
- Change in Control: Full immediate vesting of unvested RSUs if the company delists or a Qualifying Termination occurs within 12 months.
Risks/Contingencies: Separation benefits are subject to the execution and non-revocation of a release of claims. The filing notes that full details are qualified by reference to exhibits in the upcoming Form 10-K.
Investor Verification Checklist
- Verify the exact terms of the "Cause" and "Disability" definitions in the Employment Agreement.
- Confirm the specific vesting schedule for the annual time-vesting RSUs mentioned in the compensation package.
- Review the full Employment Agreement and Award Agreement filed as exhibits to the Form 10-K for the fiscal year ending June 30, 2026.
- Assess the impact of the new CEO's performance targets ($70-$100 stock price range) on future equity dilution.